Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PW Medtech GroupFRA:PWE -7.77%80 Debt-to-EBITDA is 0.18 as of Dec. 2025, which is 350% above its 10-year median of 0.04. GuruFocus rates FRA:PWE with a GF Score™ of 80/100 and a GF Value™ of €0.13 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 472 Medical Devices & Instruments companies, PW Medtech Group ranks better than 88.14% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PW Medtech Group's Debt-to-EBITDA or its related term are showing as below:
FRA:PWE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 4.06
Current: 0.13
During the past 13 years, the highest Debt-to-EBITDA Ratio of PW Medtech Group was 4.06. The lowest was 0.00. And the median was 0.04.
FRA:PWE's Debt-to-EBITDA is ranked better than 88.14% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs FRA:PWE: 0.13
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PW Medtech Group Debt-to-EBITDA Related Terms
PW Medtech Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PW Medtech Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PWE vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, PW Medtech Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
PW Medtech Group (FRA:PWE) has a Debt-to-EBITDA of 0.18 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PW Medtech Group. This is 350% above median its historical median of 0.04. According to the industry distribution chart, PW Medtech Group ranks #56 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 11.9%.
Is PW Medtech Group's Debt-to-EBITDA too high?
PW Medtech Group's current Debt-to-EBITDA of 0.18 is 350% above median its 10-year median of 0.04. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. PW Medtech Group's value of 0.18 is 89% below this industry median. Based on the distribution chart, PW Medtech Group ranks #56 out of 472 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PW Medtech Group has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PW Medtech Group ranks #56 out of 472 companies for Debt-to-EBITDA. This places PW Medtech Group in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. PW Medtech Group's value of 0.18 is 89% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 1.64, PW Medtech Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PW Medtech Group's current Debt-to-EBITDA of 0.18 is 89% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PW Medtech Group. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PW Medtech Group's current Debt-to-EBITDA is 0.18, which is 350% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
Based on GuruFocus' analysis, PW Medtech Group (FRA:PWE) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.13, compared to a current price of €0.09 — trading 31.5% below its estimated fair value. The current Debt-to-EBITDA is 0.18, which is 350% above median its 10-year median of 0.04 and 89% below the Medical Devices & Instruments industry median of 1.64. PW Medtech Group's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current Debt-to-EBITDA is 0.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.09 is trading 31.5% below its estimated GF Value™ of €0.13.
GuruFocus considers PW Medtech Group to be Significantly Undervalued.
Key valuation signals for FRA:PWE:
Debt-to-EBITDA: 0.18 (350% above median its 10-year median of 0.04)
GF Value™: €0.13 vs. price of €0.09 (31.5% below fair value)
Industry Position: 89% below the Medical Devices & Instruments median (#56 of 472)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
80GF Score
Get the complete analysis for FRA:PWE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 
